Search Result

Results for "

acute and chronic inflammatory diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) Autophagy (1) Bcl-2 Family (1) CDK (1) Complement System (2) COX (1) Cyclin G-associated Kinase (GAK) (1) ERK (1) Ferroptosis (1) Glutathione S-transferase (1) HBV (1) HCV (1) HSP (1) Interleukin Related (2) Itk (1) JNK (1) Keap1-Nrf2 (1) Microtubule/Tubulin (1) mTOR (1) Necroptosis (1) NF-κB (2) P-glycoprotein (1) p38 MAPK (2) Phosphodiesterase (PDE) (1) Phospholipase (1) Prostaglandin Receptor (1) Reactive Oxygen Species (1) Somatostatin Receptor (2) STAT (1) TNF Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (4)

By Targets:

Akt (1)

Apoptosis (1)

Autophagy (1)

Bcl-2 Family (1)

CDK (1)

Complement System (2)

COX (1)

Cyclin G-associated Kinase (GAK) (1)

ERK (1)

Ferroptosis (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HSP (1)

Interleukin Related (2)

Itk (1)

JNK (1)

Keap1-Nrf2 (1)

Microtubule/Tubulin (1)

mTOR (1)

Necroptosis (1)

NF-κB (2)

P-glycoprotein (1)

p38 MAPK (2)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (1)

Somatostatin Receptor (2)

STAT (1)

TNF Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (8)

Metabolic Disease (2)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150298

Soquelitinib CPI-818	Itk	Inflammation/Immunology Cancer
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 ⁺ cells that possess enhanced T effector function .

HY-100009

Ufenamate Flufenamic acid butyl ester; Butyl flufenamate	COX Prostaglandin Receptor	Inflammation/Immunology
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2 .

HY-14909

Bardoxolone 15+ Cited Publications CDDO; RTA 401	Keap1-Nrf2 Necroptosis	Metabolic Disease Cancer
Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-163378

C5aR1 antagonist 1	Complement System	Inflammation/Immunology
C5aR1 antagonist 1 (Compound 7e) is an orally active C5a receptor 1 (C5aR1) antagonist. C5aR1 antagonist 1 is active in DISCO and migration assays, with IC₅₀ values of 38 nM and 17 nM, respectively. C5aR1 antagonist 1 can be used for the research of acute and chronic inflammatory diseases .

HY-142701

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .

HY-142700

SSTR4 agonist 3	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 3 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .

HY-163379

C5aR1 antagonist 2	Complement System	Inflammation/Immunology
C5aR1 antagonist 2 (Compound 6a) is an orally active C5a receptor 1 (C5aR1) antagonist that shows efficacy in inhibiting the C5a-induced neutrophil count increase. C5aR1 antagonist 2 is potent in the DISCO and migration assays, with IC₅₀ values of 21 and 3 nM, respectively. C5aR1 antagonist 2 can be used for the research of acute and chronic inflammatory diseases .

HY-172135

PDE4-IN-26	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .

HY-P10854

TAT-N15	NF-κB Interleukin Related STAT Akt	Neurological Disease Inflammation/Immunology
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂ .

Cat. No.	Product Name

HY-L139

Pain-Related Compound Library	2,354 compounds
Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot. MCE supplies a unique collection of 2,354 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Pain-Related Compound Library

2,354 compounds

Pain is a kind of distressing feeling caused by the stimulation of tissue damage. According to the International Association for the Study of Pain (IASP), pain is defined as ”An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”.

Pain is usually classified according to its location, duration, underlying causes, and intensity. For example, acute and chronic pain, muscle pain, and nerve pain. Pain is the main symptom of most diseases, which seriously affects the quality of life and body function of patients. In the medical treatment of pain, anti-inflammatory drugs and opioid analgesic agents have traditionally been used, but the side effects are serious. In recent years, targeted drugs targeting the ERK/MAPK pathway or other targets have gradually become a research hotspot.

MCE supplies a unique collection of 2,354 compounds targeting key proteins in the pain system. MCE Pain-Related Compound Library is a useful tool for pain related research and anti-pain drug development.

Cat. No.	Product Name	Target	Research Area

HY-P10854

TAT-N15	NF-κB Interleukin Related STAT Akt	Neurological Disease Inflammation/Immunology
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.